About BreastSentry

BreastSentry measures the levels of two biomarkers, proneurotensin (pro-NT) and proenkephalin (pro-ENK), which are highly predictive of a woman’s risk for developing breast cancer. Elevated levels of pro-NT and decreased levels of pro-ENK are strong, independent risk factors for the development of breast cancer. 2-10 Women with elevated BreastSentry scores may need to be referred for advanced imaging tests, such as breast MRI or Ultrasound in addition to a screening mammogram.


Download BreastSentry Overview

The Science Behind The Test

Two large Swedish general population longitudinal studies were used to validate the BreastSentry test. The Malmo Diet and Cancer study (MDC) and the Malmo Preventive Project (MPP) found a significant

predictive relationship between individual pro-NT (neurotensin) and pro-ENK (enkephalin) biomarkers and the development of breast cancer.

Results from the MDC study showed a highly significant relationship between the concentration of pro-NT in the blood and the risk of developing breast cancer; the MPP study confirmed these results



Finding Breast Cancer Early Saves Lives

When Breast Cancer is found early, the five-year survival rate is 98%. 1

When Breast Cancer is found late, the five-year survival rate drops to 27%. 1


The Challenge

An estimated 20% of breast cancers are missed at least once by mammography, especially if the patient has dense breasts or has mucinous, lobular or rapidly growing cancers.1

50% of women have dense breasts and cannot benefit from mammography alone.1

BreastSentry can help you to determine if a female patient should be referred for advanced breast diagnostic procedures.

BreastSentry provides women with additional information about breast health beyond mammography.

Empowers women to identify breast cancers early, when they are most treatable.


BreastSentry Patient Selection Criteria

BreastSentry is for any woman who needs further evaluation of breast cancer risk.
​The test should not be used on women with:

  • a personal history of breast cancer
  • a confirmed or suspected genetic mutation known to increase risk of breast cancer (e.g., BRCA)
  • a history of previous radiotherapy to the chest at a young age
  • a history of kidney disease

Clinical Utility

How to Interpret the BreastSentry Results to
Guide Treatment

Clinical Interpretation & Treatment Considerations

Treatment considerations are as follows:

Pro-NT above 180pmol/L and/or pro-ENK below 44pmol/L Discuss lifestyle changes such as diet, exercise and reduced opioid use with patient.Monitor annually.

BreastSentry Average Risk Score:  Patients at Average Risk should continue to follow published recommendations from the American Cancer Society and the National Cancer Institute regarding breast cance screening as recommended by their physician.  Patients may wish to supplement the mammogram with an annual BreastSentry test to determine if they have moved into the elevated risk cohort.

BreastSentry Elevated Risk Score:  Patients at Elevated Risk should consider  additional screening such as breast ultrasound, digital breast tomosynthesis (DBT), and/or a breast MRI examination.


  1. Accessed 2019
  2. Melander O, Belting M, Manjer J, et al. Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer. Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1672-6.
  3. Melander O, Orho-Melander M, Manjer J, et al. Stable Peptide of the Endogenous Opioid Enkephalin Precursor and Breast Cancer Risk. J Clin Oncol. 2015 Aug 20;33(24):2632-8
  4. Dupouy S, Mourra N, Doan VK, et al. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie 2011;93:1369–78
  5. Melander O, Maisel AS, Almgren P, et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA 2012;308:1469
  6. Dupouy S, Viardot-Foucault V, Alifano M, et al. The Neurotensin Receptor-1 Pathway Contributes to Human Ductal Breast Cancer Progression. PLoS ONE 2009; 4(1): e4223. 3
  7. Hoff SR, Abrahamsen A-L, Samset JH, et al. Breast Cancer: Missed Interval and Screening-detected Cancer at Full-Field Digital Mammography and Screen-Film Mammography— Results from a Retrospective Review. Radiology 2012 264:2, 378-386
  8. Gartlehner G, Thaler K, Chapman A, et al. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD009632.
  9. Ho JM, Jafferjee N, Covarrubias GM, et al. Dense breasts: a review of reporting legislation and available supplemental screening options. AJR Am J Roentgenol. 203(2):449-56, 2014.
  10. Sprague BL, Gangnon RE, Burt V, et al. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst. 106(10), 2014.
  11. Yaghjyan L, Colditz GA, Collins LC, et al. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst. 103(15):1179-89, 2011.
  12. Accessed 2019

Harnessing the Power of Gene Expression for
Early Cancer Detection